PharmiWeb.com: The Heart of Life Sciences on the Web
WEBJ.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region. Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions. Hamburg, Germany, and Toulouse, France, 20 September 2024:
Kelso Pharma announces first product launch - PharmiWeb.com
WEBJan 30, 2023 · Kelso Pharma, the growing UK based specialty pharma business, has announced its first product launch with the release to the UK prescription medicines market of Acepiro ® (Acetylcysteine) 600mg effervescent tablets.. Acepiro (Acetylcysteine) is indicated in adults as a mucolytic agent for the treatment of respiratory tract diseases in which a reduction in bronchial secretion viscosity is ...
Top 12 Clinical Research Organisations (CROs) in 2023
WEBFeb 23, 2023 · The global clinical trials market was estimated to be worth $38.7 billion in 2021 and is expected to reach £52 billion by 2026. In this article, we look at the top 12 CROs in the world, highlighting the companies driving this considerable growth and accelerating research and development across the globe.. ICON. Recognised as the world’s largest and most comprehensive CRO powered by ...
Lemonex announces approval of IND application for mRNA …
WEBAug 9, 2023 · SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 9th of August that an Investigational New Drug (IND) application has been approved by the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery ...
Puradigm, LLC announces successful tests of its proactive air and ...
WEBAug 10, 2020 · Results from a study done by the University of Florida using the SARS-CoV-2 virus show a significant decrease in infectivity of the virus immediately after exposure to Puradigm's technology and show the virus was undetectable after 24 hours of exposure to their technology. SAN DIEGO, Calif., Aug. 10, 2020 /PRNewsw...
Calypso Enters into Agreement to Be Acquired by Novartis
WEBJan 8, 2024 · AMSTERDAM, the Netherlands, January 08, 2024 / B3C newswire / -- Calypso Biotech BV (‘Calypso’), a leader in the development of Interleukin15 (IL-15) targeted therapies, announced today that it has entered into an agreement to be acquired by Novartis AG (‘Novartis’). Calypso’s shareholders will receive an upfront payment of …
LILLY RECEIVES MHRA MARKETING AUTHORISATION IN GREAT …
WEBJan 29, 2024 · BASINGSTOKE, 26 th January 2024 – Eli Lilly and Company announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for tirzepatide solution for injection in an alternative KwikPen ® presentation, for two indications:. For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and ...
DoseMe Expands Its Reseller Agreement with Primum Pharma into …
WEBFeb 2, 2024 · JUPITER, Fla.-- (BUSINESS WIRE)-- DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced its expanded agreement with Primum Pharma as its reseller and distribution partner in the MEA market. Recently, the two companies announced alignment in ...
Noramco Announces the Acquisition of the Cambrex Drug …
WEBNov 2, 2023 · WILMINGTON, Del.-- (BUSINESS WIRE)--Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals. This acquisition will …
The Liposome-Based PROTAC Strategy - PharmiWeb.com
WEBJan 22, 2024 · Recently, a new split-and-mix PROTAC (SM-PROTAC) system based on liposome self-assembly, known as LipoSM-PROTAC, was reported in the Journal of the American Chemical Society. The LipoSM-PROTAC system exhibits selective degradation of target proteins, with folate serving as a key ligand. In this study, the researchers used the estrogen receptor ...
Skip to content